메뉴 건너뛰기




Volumn 72, Issue 3, 1999, Pages 162-169

Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study

Author keywords

Cisplatin; Ovarian cancer; Paclitaxel; Primary peritoneal cancer; Recurrence; Topotecan

Indexed keywords

CISPLATIN; TOPOTECAN;

EID: 0032708102     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199911)72:3<162::AID-JSO9>3.0.CO;2-0     Document Type: Article
Times cited : (14)

References (24)
  • 2
    • 0030054309 scopus 로고    scopus 로고
    • Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
    • Mcguire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
    • (1996) N Engl J Med , vol.334 , pp. 1-6
    • Mcguire, W.P.1    Hoskins, W.J.2    Brady, M.F.3
  • 3
    • 0000264166 scopus 로고    scopus 로고
    • Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment for advanced ovarian cancer: Mature results of the EORTC-GCCG, NO-COVA, NCIC CTG and scottish intergroup trial
    • Stuart G, Bertelsen K, Magioni C, et al.: Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment for advanced ovarian cancer: Mature results of the EORTC-GCCG, NO-COVA, NCIC CTG and Scottish Intergroup Trial [Abstract]. Proc Am Soc Clin Oncol 1998;17:361A.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Stuart, G.1    Bertelsen, K.2    Magioni, C.3
  • 4
    • 0024522049 scopus 로고
    • Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design for phase II trials
    • Blackledge G, Lawton F, Redman C, et al.: Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design for phase II trials. BMJ 1989;59:650-653.
    • (1989) BMJ , vol.59 , pp. 650-653
    • Blackledge, G.1    Lawton, F.2    Redman, C.3
  • 5
    • 0030915166 scopus 로고    scopus 로고
    • Treatment of recurrent ovarian cancer: Increasing options - "Recurrent results."
    • Ozols RF: Treatment of recurrent ovarian cancer: Increasing options - "recurrent results." J Clin Oncol 1997;15:2177-2180.
    • (1997) J Clin Oncol , vol.15 , pp. 2177-2180
    • Ozols, R.F.1
  • 6
    • 0000626027 scopus 로고
    • A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer
    • Armstrong D, Rowinsky E, Donehower R, et al.: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer [Abstract]. Proc Am Soc Clin Oncol 1995;14:275A.
    • (1995) Proc Am Soc Clin Oncol , vol.14
    • Armstrong, D.1    Rowinsky, E.2    Donehower, R.3
  • 7
    • 10544229791 scopus 로고    scopus 로고
    • Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: Results of large European phase II study
    • Creemers GJ, Bolis G, Gore M, et al.: Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: Results of large European phase II study. J Clin Oncol 1996;14:3056-3061.
    • (1996) J Clin Oncol , vol.14 , pp. 3056-3061
    • Creemers, G.J.1    Bolis, G.2    Gore, M.3
  • 8
    • 0000391321 scopus 로고    scopus 로고
    • Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International topotecan study group trial
    • Gordon A, Bookman M, Malmstrom H, et al.: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial [Abstract]. Proc Am Soc Clin Oncol 1996;15:282A.
    • (1996) Proc Am Soc Clin Oncol , vol.15
    • Gordon, A.1    Bookman, M.2    Malmstrom, H.3
  • 9
    • 9244247616 scopus 로고    scopus 로고
    • Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma
    • Kudelka AP, Tresukosol D, Edwards CL, et al.: Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552-1557.
    • (1996) J Clin Oncol , vol.14 , pp. 1552-1557
    • Kudelka, A.P.1    Tresukosol, D.2    Edwards, C.L.3
  • 10
    • 0003241320 scopus 로고    scopus 로고
    • Final analysis of a phase III randomized study of topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian cancer (OC): International topotecan study group
    • Gordon A, Carmichael J, Malfetano J, et al.: Final analysis of a phase III randomized study of topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian cancer (OC): International Topotecan Study Group [Abstract]. Proc Am Soc Clin Oncol 1998;17:356A.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Gordon, A.1    Carmichael, J.2    Malfetano, J.3
  • 11
    • 0030900145 scopus 로고    scopus 로고
    • Topotecan versus paclitaxel for treatment of recurrent epithelial ovarian cancer
    • ten Bokkel Huinink W, Gore M, Carmichael J, et al.: Topotecan versus paclitaxel for treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-2193.
    • (1997) J Clin Oncol , vol.15 , pp. 2183-2193
    • Ten Bokkel Huinink, W.1    Gore, M.2    Carmichael, J.3
  • 12
    • 0031894188 scopus 로고    scopus 로고
    • Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: A gynecologic oncology group study
    • Rose PG, Blessing JA, Mayer AR, et al.: Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 1998;16:405-410.
    • (1998) J Clin Oncol , vol.16 , pp. 405-410
    • Rose, P.G.1    Blessing, J.A.2    Mayer, A.R.3
  • 13
    • 0030881725 scopus 로고    scopus 로고
    • Salvage weekly paclitaxel in recurrent ovarian cancer
    • Abu-Rustum NR, Aghajanian C, Barakat RR, et al.: Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 1997;24(Suppl. 15):62-67.
    • (1997) Semin Oncol , vol.24 , Issue.SUPPL. 15 , pp. 62-67
    • Abu-Rustum, N.R.1    Aghajanian, C.2    Barakat, R.R.3
  • 14
    • 0002360126 scopus 로고    scopus 로고
    • Phase I study of weekly cisplatin (P) and weekly or 4 weekly Taxol (T): A highly active regimen in advanced epithelial ovarian cancer (OC)
    • van der Burg MEL, de Wit R, Stoter G, et al.: Phase I study of weekly cisplatin (P) and weekly or 4 weekly Taxol (T): a highly active regimen in advanced epithelial ovarian cancer (OC) [Abstract], Proc Am Soc Clin Oncol 1998;17:355A.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Van Der Burg, M.E.L.1    De Wit, R.2    Stoter, G.3
  • 15
    • 0031055830 scopus 로고    scopus 로고
    • Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
    • Muggia FM, Hainsworth JD, Jeffers S, et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-993.
    • (1997) J Clin Oncol , vol.15 , pp. 987-993
    • Muggia, F.M.1    Hainsworth, J.D.2    Jeffers, S.3
  • 16
    • 0003182226 scopus 로고
    • Gemcitabine (Gem) in cisplatin-resistant ovarian cancer
    • Kaufmann M, Bauknecht T, Jonat W, et al.: Gemcitabine (Gem) in cisplatin-resistant ovarian cancer [Abstract]. Proc Am Soc Clin Oncol 1995;14:272A.
    • (1995) Proc Am Soc Clin Oncol , vol.14
    • Kaufmann, M.1    Bauknecht, T.2    Jonat, W.3
  • 17
    • 0027447420 scopus 로고
    • The current status of camptothecin analogues as antitumor agents
    • Slichenmyer WJ, Rowinsky EK, Donehower RC, et al.: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-291.
    • (1993) J Natl Cancer Inst , vol.85 , pp. 271-291
    • Slichenmyer, W.J.1    Rowinsky, E.K.2    Donehower, R.C.3
  • 18
    • 0001951950 scopus 로고
    • Combination regimens with topotecan in animal tumor models
    • Johnson RK, McCabe FL, Yu Y: Combination regimens with topotecan in animal tumor models. Ann Oncol 1992;3:85-88.
    • (1992) Ann Oncol , vol.3 , pp. 85-88
    • Johnson, R.K.1    McCabe, F.L.2    Yu, Y.3
  • 19
    • 0031905299 scopus 로고    scopus 로고
    • In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems
    • Romanelli S, Perego P, Pratesi G, et al.: In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 1998;41:385-390.
    • (1998) Cancer Chemother Pharmacol , vol.41 , pp. 385-390
    • Romanelli, S.1    Perego, P.2    Pratesi, G.3
  • 20
    • 10544249871 scopus 로고    scopus 로고
    • Sequences of topotecan and cisplatin: A phase I, pharmacologic, and in vitro study to examine sequence dependence
    • Rowinsky EK, Kaufmann SH, Baker SD, et al.: Sequences of topotecan and cisplatin: A phase I, pharmacologic, and in vitro study to examine sequence dependence. J Clin Oncol 1996;14: 3074-3084.
    • (1996) J Clin Oncol , vol.14 , pp. 3074-3084
    • Rowinsky, E.K.1    Kaufmann, S.H.2    Baker, S.D.3
  • 21
    • 0027999967 scopus 로고
    • Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group B study
    • Miller AA, Hargis JB, Lilenbaum RC, et al.: Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A Cancer and Leukemia Group B study. J Clin Oncol 1994;12: 2743-2750.
    • (1994) J Clin Oncol , vol.12 , pp. 2743-2750
    • Miller, A.A.1    Hargis, J.B.2    Lilenbaum, R.C.3    Et, A.4
  • 22
    • 0024420685 scopus 로고
    • Arrest of replication forks by drug stabilized topoisomerase I-DNA cleavable complexes as mechanism of cell killing by camptothecin
    • Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug stabilized topoisomerase I-DNA cleavable complexes as mechanism of cell killing by camptothecin. Cancer Res 1989;49: 5077-5082.
    • (1989) Cancer Res , vol.49 , pp. 5077-5082
    • Hsiang, Y.H.1    Lihou, M.G.2    Liu, L.F.3
  • 23
    • 0029993118 scopus 로고    scopus 로고
    • Treatment related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel
    • Miller AA, Lilenbaum RC, Lynch TJ, et al.: Treatment related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel . J Clin Oncol 1996;14:1964-1965.
    • (1996) J Clin Oncol , vol.14 , pp. 1964-1965
    • Miller, A.A.1    Lilenbaum, R.C.2    Lynch, T.J.3
  • 24
    • 0343976836 scopus 로고    scopus 로고
    • Phase I study of continuous IV infusion topotecan (TT) in combination with cisplatin (C) in patients with advanced cancer (CALGB 9462)
    • Lilenbaum RC, Miller AA, Batist G, et al.: Phase I study of continuous IV infusion topotecan (TT) in combination with cisplatin (C) in patients with advanced cancer (CALGB 9462) [Abstract]. Proc Am Soc Clin Oncol 1996;15:485A.
    • (1996) Proc Am Soc Clin Oncol , vol.15
    • Lilenbaum, R.C.1    Miller, A.A.2    Batist, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.